A 42-year-old woman with a 5-year history of asthma and chronic nasal obstruction presents with recurrent episodes of acute rhinosinusitis. Nasal endoscopy reveals multiple pale polyps bilaterally. She reports that her symptoms worsen with aspirin and NSAIDs. High-resolution CT PNS shows bilateral ethmoid and maxillary sinus opacification with polypoidal masses. Which of the following is the most appropriate first-line pharmacological management?

Explanation

## First-Line Management of CRSwNP: Intranasal Corticosteroids ### Clinical Context This patient has: - Chronic rhinosinusitis with nasal polyposis (bilateral pale polyps, sinus opacification) - **Samter's triad** features: asthma + chronic rhinosinusitis + NSAID sensitivity - Type 2 inflammation (eosinophilic polyposis) ### Treatment Algorithm ```mermaid flowchart TD A["CRSwNP diagnosed"]:::outcome --> B{"Symptomatic?"}:::decision B -->|"Yes"| C["Intranasal corticosteroid"]:::action C --> D{"Response at 3-6 months?"}:::decision D -->|"Good"| E["Continue INCS"]:::action D -->|"Inadequate"| F{"Severe/recurrent?"}:::decision F -->|"Yes"| G["Consider FESS"]:::action F -->|"Yes, refractory"| H["Biologic: Dupilumab"]:::action B -->|"No"| I["Observation"]:::action ``` ### Why Intranasal Corticosteroids (INCS) First? **Key Point:** Intranasal corticosteroids are the gold-standard first-line therapy for CRSwNP. They reduce polyp size, improve nasal airflow, and decrease inflammatory markers (IL-5, eosinophils). **High-Yield:** INCS work by: 1. Suppressing Type 2 cytokines (IL-4, IL-5, IL-13) 2. Reducing eosinophilic infiltration 3. Decreasing mucin production and tissue edema 4. Promoting polyp regression (30–50% size reduction in responders) ### Mechanism & Efficacy | Agent | Potency | Bioavailability | Indication | Notes | |-------|---------|-----------------|-----------|-------| | **Mometasone furoate** | High | <1% systemic | First-line CRSwNP | Excellent safety profile | | **Fluticasone propionate** | High | <2% systemic | First-line CRSwNP | Also effective; comparable efficacy | | **Beclomethasone** | Moderate | Low | Alternative | Less potent than mometasone | **Clinical Pearl:** Intranasal corticosteroids have minimal systemic absorption (<1–2%) and are safe for long-term use, even in children. ### Why NOT the Other Options? **Oral Prednisolone (Option 1):** While systemic corticosteroids can provide rapid symptom relief and polyp shrinkage, they are reserved for acute exacerbations or when INCS fail. Long-term oral steroids carry significant risks (osteoporosis, immunosuppression, metabolic effects) and are not first-line. INCS should be tried for 3–6 months before escalating to oral therapy. **Functional Endoscopic Sinus Surgery (Option 2):** FESS is indicated for: - Failure of medical management after 3–6 months of INCS - Recurrent acute exacerbations despite INCS - Severe symptoms affecting quality of life This patient has not yet received an adequate trial of INCS, so surgery is premature. **Dupilumab (Option 3):** Dupilumab (anti-IL-4 receptor α) is a biologic indicated for: - Moderate-to-severe CRSwNP refractory to INCS and FESS - Severe asthma with eosinophilic or Type 2 phenotype It is NOT first-line and is reserved for patients who fail conventional therapy due to cost and the need for ongoing monitoring. **Tip:** Remember the stepwise approach: **INCS → FESS → Biologic agents**. Do not skip steps or jump to invasive/expensive therapy prematurely. ### Samter's Triad Context This patient's NSAID sensitivity and asthma indicate a **Type 2 inflammatory phenotype**, which responds well to INCS and is an indication for biologic therapy (dupilumab) if medical management fails. Avoid NSAIDs; use acetaminophen or COX-2 selective inhibitors (with caution).